The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Engineered T Cells-Global Market Insights and Sales Trends 2024
Synopsis
The global Engineered T Cells market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Engineered T Cells in various end use industries. The expanding demands from the Hospitals, Cancer Research Centers and Clinics,, are propelling Engineered T Cells market. Tumor Infiltrating Lymphocytes, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the T Cell Receptor {TCR} segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Engineered T Cells market, driven by demand from China, the second largest economy with some signs of stabilising, the Engineered T Cells market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Engineered T Cells, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Engineered T Cells market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Engineered T Cells market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Engineered T Cells sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Engineered T Cells covered in this report include Autolus Limited, Bellicum Pharmaceuticals, Cells Medica, Elli Lilly and Company, Gilead Sciences, Juno Therapeutics, Novartis, Oxford Biomedica and Pfizer, etc.
The global Engineered T Cells market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Precision Bioscience
Redmile Group
Seeking Alpha
Unum Therapeutics
Global Engineered T Cells market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Engineered T Cells market, Segment by Type:
Tumor Infiltrating Lymphocytes
T Cell Receptor {TCR}
Chimeric Antigen Receptor(CAR)
Global Engineered T Cells market, by Application
Hospitals
Cancer Research Centers
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Engineered T Cells companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Engineered T Cells market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Engineered T Cells in various end use industries. The expanding demands from the Hospitals, Cancer Research Centers and Clinics,, are propelling Engineered T Cells market. Tumor Infiltrating Lymphocytes, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the T Cell Receptor {TCR} segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Engineered T Cells market, driven by demand from China, the second largest economy with some signs of stabilising, the Engineered T Cells market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Engineered T Cells, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Engineered T Cells market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Engineered T Cells market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Engineered T Cells sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Engineered T Cells covered in this report include Autolus Limited, Bellicum Pharmaceuticals, Cells Medica, Elli Lilly and Company, Gilead Sciences, Juno Therapeutics, Novartis, Oxford Biomedica and Pfizer, etc.
The global Engineered T Cells market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Precision Bioscience
Redmile Group
Seeking Alpha
Unum Therapeutics
Global Engineered T Cells market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Engineered T Cells market, Segment by Type:
Tumor Infiltrating Lymphocytes
T Cell Receptor {TCR}
Chimeric Antigen Receptor(CAR)
Global Engineered T Cells market, by Application
Hospitals
Cancer Research Centers
Clinics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Engineered T Cells companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Engineered T Cells
1.1 Engineered T Cells Market Overview
1.1.1 Engineered T Cells Product Scope
1.1.2 Engineered T Cells Market Status and Outlook
1.2 Global Engineered T Cells Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Engineered T Cells Market Size by Region (2018-2029)
1.4 Global Engineered T Cells Historic Market Size by Region (2018-2023)
1.5 Global Engineered T Cells Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Engineered T Cells Market Size (2018-2029)
1.6.1 North America Engineered T Cells Market Size (2018-2029)
1.6.2 Europe Engineered T Cells Market Size (2018-2029)
1.6.3 Asia-Pacific Engineered T Cells Market Size (2018-2029)
1.6.4 Latin America Engineered T Cells Market Size (2018-2029)
1.6.5 Middle East & Africa Engineered T Cells Market Size (2018-2029)
2 Engineered T Cells Market by Type
2.1 Introduction
2.1.1 Tumor Infiltrating Lymphocytes
2.1.2 T Cell Receptor {TCR}
2.1.3 Chimeric Antigen Receptor(CAR)
2.2 Global Engineered T Cells Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Engineered T Cells Historic Market Size by Type (2018-2023)
2.2.2 Global Engineered T Cells Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Engineered T Cells Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Engineered T Cells Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Engineered T Cells Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Engineered T Cells Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Engineered T Cells Revenue Breakdown by Type (2018-2029)
3 Engineered T Cells Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Cancer Research Centers
3.1.3 Clinics
3.2 Global Engineered T Cells Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Engineered T Cells Historic Market Size by Application (2018-2023)
3.2.2 Global Engineered T Cells Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Engineered T Cells Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Engineered T Cells Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Engineered T Cells Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Engineered T Cells Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Engineered T Cells Revenue Breakdown by Application (2018-2029)
4 Engineered T Cells Competition Analysis by Players
4.1 Global Engineered T Cells Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Engineered T Cells as of 2022)
4.3 Date of Key Players Enter into Engineered T Cells Market
4.4 Global Top Players Engineered T Cells Headquarters and Area Served
4.5 Key Players Engineered T Cells Product Solution and Service
4.6 Competitive Status
4.6.1 Engineered T Cells Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Autolus Limited
5.1.1 Autolus Limited Profile
5.1.2 Autolus Limited Main Business
5.1.3 Autolus Limited Engineered T Cells Products, Services and Solutions
5.1.4 Autolus Limited Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.1.5 Autolus Limited Recent Developments
5.2 Bellicum Pharmaceuticals
5.2.1 Bellicum Pharmaceuticals Profile
5.2.2 Bellicum Pharmaceuticals Main Business
5.2.3 Bellicum Pharmaceuticals Engineered T Cells Products, Services and Solutions
5.2.4 Bellicum Pharmaceuticals Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.2.5 Bellicum Pharmaceuticals Recent Developments
5.3 Cells Medica
5.3.1 Cells Medica Profile
5.3.2 Cells Medica Main Business
5.3.3 Cells Medica Engineered T Cells Products, Services and Solutions
5.3.4 Cells Medica Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.3.5 Elli Lilly and Company Recent Developments
5.4 Elli Lilly and Company
5.4.1 Elli Lilly and Company Profile
5.4.2 Elli Lilly and Company Main Business
5.4.3 Elli Lilly and Company Engineered T Cells Products, Services and Solutions
5.4.4 Elli Lilly and Company Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.4.5 Elli Lilly and Company Recent Developments
5.5 Gilead Sciences
5.5.1 Gilead Sciences Profile
5.5.2 Gilead Sciences Main Business
5.5.3 Gilead Sciences Engineered T Cells Products, Services and Solutions
5.5.4 Gilead Sciences Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.5.5 Gilead Sciences Recent Developments
5.6 Juno Therapeutics
5.6.1 Juno Therapeutics Profile
5.6.2 Juno Therapeutics Main Business
5.6.3 Juno Therapeutics Engineered T Cells Products, Services and Solutions
5.6.4 Juno Therapeutics Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.6.5 Juno Therapeutics Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Engineered T Cells Products, Services and Solutions
5.7.4 Novartis Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Oxford Biomedica
5.8.1 Oxford Biomedica Profile
5.8.2 Oxford Biomedica Main Business
5.8.3 Oxford Biomedica Engineered T Cells Products, Services and Solutions
5.8.4 Oxford Biomedica Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.8.5 Oxford Biomedica Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Engineered T Cells Products, Services and Solutions
5.9.4 Pfizer Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Precision Bioscience
5.10.1 Precision Bioscience Profile
5.10.2 Precision Bioscience Main Business
5.10.3 Precision Bioscience Engineered T Cells Products, Services and Solutions
5.10.4 Precision Bioscience Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.10.5 Precision Bioscience Recent Developments
5.11 Redmile Group
5.11.1 Redmile Group Profile
5.11.2 Redmile Group Main Business
5.11.3 Redmile Group Engineered T Cells Products, Services and Solutions
5.11.4 Redmile Group Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.11.5 Redmile Group Recent Developments
5.12 Seeking Alpha
5.12.1 Seeking Alpha Profile
5.12.2 Seeking Alpha Main Business
5.12.3 Seeking Alpha Engineered T Cells Products, Services and Solutions
5.12.4 Seeking Alpha Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.12.5 Seeking Alpha Recent Developments
5.13 Unum Therapeutics
5.13.1 Unum Therapeutics Profile
5.13.2 Unum Therapeutics Main Business
5.13.3 Unum Therapeutics Engineered T Cells Products, Services and Solutions
5.13.4 Unum Therapeutics Engineered T Cells Revenue (US$ Million) & (2018-2023)
5.13.5 Unum Therapeutics Recent Developments
6 North America
6.1 North America Engineered T Cells Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Engineered T Cells Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Engineered T Cells Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Engineered T Cells Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Engineered T Cells Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Engineered T Cells Market Dynamics
11.1 Engineered T Cells Industry Trends
11.2 Engineered T Cells Market Drivers
11.3 Engineered T Cells Market Challenges
11.4 Engineered T Cells Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
